Abstract: The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
Type:
Application
Filed:
July 2, 2024
Publication date:
January 9, 2025
Applicants:
Genentech, Inc., Novartis AG
Inventors:
Ryan Patrick OWEN, Ahmar IQBAL, Robert A. WOOD
Abstract: The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-trifluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of cancers.
Type:
Grant
Filed:
May 12, 2020
Date of Patent:
January 7, 2025
Assignee:
NOVARTIS AG
Inventors:
Cornelius Stephen Harlacher, Zaixing Li, Liladhar Murlidhar Waykole
Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
Type:
Grant
Filed:
July 11, 2022
Date of Patent:
January 7, 2025
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania, Dana Farber Cancer Institute, Inc., President and Fellows of Harvard College
Inventors:
Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
Abstract: This application discloses anti-CCR7 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
Type:
Grant
Filed:
February 3, 2023
Date of Patent:
December 31, 2024
Assignee:
NOVARTIS AG
Inventors:
Steven Bender, Tracy Charlton, Anna Galkin, Bernhard Hubert Geierstanger, Scott Martin Glaser, Shailaja Kasibhatla, Mark Knuth, Sabine Rottmann, Sarah Rue, Glen Spraggon, Tetsuo Uno
Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
Type:
Grant
Filed:
September 1, 2023
Date of Patent:
December 24, 2024
Assignee:
NOVARTIS AG
Inventors:
Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Yf Ting
Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
Type:
Grant
Filed:
June 6, 2022
Date of Patent:
December 24, 2024
Assignee:
Novartis AG
Inventors:
Anthony Edward Boitano, Matthew Burger, Susan E. Cellitti, Michael P. Cooke, Catrin Finner, Bernhard Hubert Geierstanger, Yunho Jin, Si Tuen Lee-Hoeflich, HongNgoc Thi Pham, Siew Ho Schleyer, Kathrin Tissot, Tetsuo Uno, Ben Wen
Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
Type:
Grant
Filed:
July 23, 2019
Date of Patent:
December 17, 2024
Assignee:
Novartis AG
Inventors:
Christopher Farady, Nina Gommermann, Philipp Janser, Angela MacKay, Henri Mattes, Nikolaus Johannes Stiefl, Juraj Velcicky
Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
Type:
Grant
Filed:
August 10, 2021
Date of Patent:
December 10, 2024
Assignee:
Novartis AG
Inventors:
David R. Anderson, Robert A. Volkmann, Frank S. Menniti
Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
December 10, 2024
Assignees:
Novartis AG, The Trustees of the University of Pennsylvania
Inventors:
Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
Type:
Grant
Filed:
December 14, 2021
Date of Patent:
December 10, 2024
Assignee:
Novartis AG
Inventors:
David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
Abstract: Disclosed herein, inter alia, are compositions and methods for targeting E3 ligases. In an aspect is a targeted protein degrader including 1) a targeted protein binder and 2) an E3 Ubiquitin ligase binder, wherein the E3 Ubiquitin ligase is human RNF4 or human RNF114. In an aspect is provided a pharmaceutical composition including a compound as described herein, including embodiments, and a pharmaceutically acceptable excipient.
Type:
Grant
Filed:
October 9, 2019
Date of Patent:
December 10, 2024
Assignees:
The Regents of the University of California, Novartis AG
Inventors:
Jessica Spradlin, Carl C. Ward, Daniel K. Nomura, Markus Schirle, John A. Tallarico, Jeffrey McKenna, Thomas John Maimone, Xirui Hu
Abstract: An automatic drug delivery device, for dispensing a fluid medicament, includes: a longitudinal housing; a removable cap; a syringe assembly having a hollow syringe body and an injection needle; and a drive mechanism. The loaded drive mechanism is operatively coupled with a safety shield movable within the longitudinal housing. The safety shield is biased into a proximal position in which it protrudes out of the proximal end of the longitudinal housing in order to cover a needle tip of the injection needle. The safety shield is movable into a distal position in which the injection needle is exposed for injection. The device includes a feedback mechanism providing a visual feedback to the user indicating an actual state of operation. The feedback mechanism includes a visual indicator which appears in a transparent window on the distal end of the housing.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
December 10, 2024
Assignee:
Novartis AG
Inventors:
Jacques Appy, Andrew Bryant, Neil Cammish, Congyi Huang, John Palmer-Felgate, Claudio Rossi, Oliver Shergold, Gianluca Tordi, Adrian Francios Von Muralt, Mark Horlock
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Grant
Filed:
May 18, 2023
Date of Patent:
December 3, 2024
Assignee:
Novartis AG
Inventors:
Mallesh Bushaboina, Xin Chen, Atwood Kim Cheung, Andrew James Culshaw, Timothy Brian Hurley, Nancy Labbe-Giguere, Wolfgang Miltz, David Orain, Tajesh Patel, Srinivasan Rajagopalan, Till Roehn, David Andrew Sandham, Gebhard Thoma, Ritesh Bhanudasji Tichkule, Rudolf Wälchli
Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
Type:
Grant
Filed:
May 3, 2022
Date of Patent:
November 19, 2024
Assignee:
Novartis AG
Inventors:
David R. Anderson, Robert A. Volkmann, Frank S. Menniti
Abstract: The disclosure is directed to novel predictive methods and personalized therapies for treating dry eye disease (DED). Specifically, this disclosure relates to methods of treating a patient having DED by selectively administering a TNF? antagonist, e.g., a TNF? antibody, such as LME636, to the patient on the basis of that patient being genetically predisposed to have a favorable response to treatment with the TNF? antagonist. Also disclosed herein are transmittable forms of information, diagnostic methods, and kits useful in predicting the likelihood that a patient having DED will respond to treatment with a TNF? antagonist, e.g., a TNF? antibody, such as LME636.
Type:
Grant
Filed:
June 19, 2017
Date of Patent:
November 19, 2024
Assignee:
Novartis AG
Inventors:
Yunsheng He, Christian Leisner, Michael Wald, Georges Weissgerber
Abstract: The present disclosure provides PROTAC compounds represented by Formula (A): D-L-DSM (A), or an enantiomer, a diastereoisomer, and/or a pharmaceutically acceptable salt of any one of the foregoing, wherein: DSM is a degradation signaling compound {e.g., an E3 ubiquitin ligase recruitment ligand, such as a CRBN ligand or a VHL ligand) covalently attached to a linker L; L is a linker that covalently attaches DSM to D; and D is a Bcl-xL inhibitor compound of Formula (I) or Formula (II) covalently attached to the linker L: (I); (II) wherein the definitions for the variables are described herein. Also provided are pharmaceutical compositions comprising the PROTAC compounds of the present disclosure and methods of use and methods of making thereof.
Type:
Application
Filed:
February 1, 2022
Publication date:
November 14, 2024
Applicants:
Les Laboratoires Servier, Novartis AG
Inventors:
András Herner, Piroska Markacz, Gang Liu, Katsumasa Nakajima, Tibor Novak, Georges-Alain Franzetti, Jérôme-Benoit Starck, Frédéric Colland, Patrice Desos, Attila Paczal, Bianka Szokol, Mátyás Timari, Vilibald Kun, Matthew Burger, Joseph D'Alessio, Katherine Seiss, Ranny Thomas, Liang Zhao
Abstract: The invention relates to a method for the manufacture of a compound of Formula I as mentioned above, or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein A, LG, n and m are as defined in the Summary of the Invention.
Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
Type:
Grant
Filed:
January 13, 2022
Date of Patent:
November 12, 2024
Assignee:
Novartis AG
Inventors:
Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
Type:
Grant
Filed:
November 11, 2019
Date of Patent:
November 5, 2024
Assignee:
Novartis AG
Inventors:
Jason Katz, William Roush, Hans Martin Seidel, Dong-Ming Shen, Shankar Venkatraman